287979-27-5 Usage
Uses
Used in Pharmaceutical Research and Development:
6-(2,2,2-Trifluoroethoxy)nicotinic acid methyl ester is used as a key intermediate in the synthesis of potential therapeutic agents for various medical applications. Its unique structure, which includes a nicotinic acid backbone and a trifluoroethoxy group, may contribute to the development of new drugs with enhanced biological activity.
Used in Drug Synthesis:
In the pharmaceutical industry, 6-(2,2,2-Trifluoroethoxy)nicotinic acid methyl ester is used as a building block for the creation of novel drug molecules. Its chemical properties allow it to be incorporated into the structures of potential medications, which could lead to the discovery of new treatments for various diseases and conditions.
Used in Chemical Research:
6-(2,2,2-Trifluoroethoxy)nicotinic acid methyl ester is also utilized in chemical research to study its properties and potential reactions with other compounds. This research can provide valuable insights into the compound's behavior and may lead to the identification of new applications or modifications that could improve its utility in pharmaceutical development.
Check Digit Verification of cas no
The CAS Registry Mumber 287979-27-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,7,9,7 and 9 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 287979-27:
(8*2)+(7*8)+(6*7)+(5*9)+(4*7)+(3*9)+(2*2)+(1*7)=225
225 % 10 = 5
So 287979-27-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H8F3NO3/c1-15-8(14)6-2-3-7(13-4-6)16-5-9(10,11)12/h2-4H,5H2,1H3
287979-27-5Relevant academic research and scientific papers
AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
-
Paragraph 0256, (2018/09/12)
The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
INDOLYLMETHYL-MORPHOLINE DERIVATIVES AS KINASE INHIBITORS
-
Page/Page column 57-58, (2010/12/31)
A series of morpholine derivatives, substituted in the 4-position by a substituted carbonyl or sulfonyl moiety, and in the 3-position by an optionally substituted indol-3-ylmethyl group, being selective inhibitors of PI3 kinase enzymes, are accordingly of
